Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2012, Article ID 420792, 5 pages
http://dx.doi.org/10.1155/2012/420792
Research Article

C-Peptide Versus Insulin: Relationships with Risk Biomarkers of Cardiovascular Disease in Metabolic Syndrome in Young Arab Females

College of Health Sciences, University of Sharjah, P.O. Box 27272, Sharjah, UAE

Received 11 April 2012; Revised 14 June 2012; Accepted 18 June 2012

Academic Editor: Panayota Mitrou

Copyright © 2012 A. Abdullah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. The World Health Organization, “The top 10 causes of death,” March, 2012, http://www.who.int/mediacentre/factsheets/fs310/en/index2.html.
  2. K. G. M. M. Alberti, R. H. Eckel, S. M. Grundy et al., “Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity,” Circulation, vol. 120, no. 16, pp. 1640–1645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. K. G. M. M. Alberti, P. Zimmet, and J. Shaw, “Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation,” Diabetic Medicine, vol. 23, no. 5, pp. 469–480, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Bajaj, S. Suraamornkul, S. Kashyap, K. Cusi, L. Mandarino, and R. A. DeFronzo, “Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 9, pp. 4649–4655, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. C. M. Ballantyne, R. C. Hoogeveen, A. M. McNeill et al., “Metabolic syndrome risk for cardiovascular disease and diabetes in the ARIC study,” International Journal of Obesity, vol. 32, no. 2, pp. S21–S24, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Beckman, M. A. Creager, and P. Libby, “Diabetes and atherosclerosis epidemiology, pathophysiology, and management,” Journal of the American Medical Association, vol. 287, no. 19, pp. 2570–2581, 2002. View at Google Scholar · View at Scopus
  7. D. F. Steiner, “Evidence for a precursor in the biosynthesis of insulin,” Transactions of the New York Academy of Sciences, vol. 30, no. 1, pp. 60–68, 1967. View at Google Scholar · View at Scopus
  8. D. F. Steiner, S. Y. Park, J. Støy, L. H. Philipson, and G. I. Bell, “A brief perspective on insulin production,” Diabetes, Obesity and Metabolism, vol. 11, supplement 4, pp. 189–196, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Pramanik, K. Ekberg, Z. Zhong et al., “C-peptide binding to human cell membranes: importance of Glu27,” Biochemical and Biophysical Research Communications, vol. 284, no. 1, pp. 94–98, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. C. E. Hills, N. Al-Rasheed, N. Al-Rasheed, G. B. Willars, and N. J. Brunskill, “C-peptide reverses TGF-β1-induced changes in renal proximal tubular cells: implications for treatment of diabetic nephropathy,” American Journal of Physiology, vol. 296, no. 3, pp. F614–F621, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Wahren, K. Ekberg, and H. Jörnvall, “C-peptide is a bioactive peptide,” Diabetologia, vol. 50, no. 3, pp. 503–509, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Wahren, J. Shafqat, J. Johansson, A. Chibalin, K. Ekberg, and H. Jörnvall, “Molecular and cellular effects of C-peptide—new perspectives on an old peptide,” Experimental Diabesity Research, vol. 5, no. 1, pp. 15–23, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. R. S. Ahima, “Adipose tissue as an endocrine organ.,” Obesity, vol. 14, supplement 5, pp. S42S–249S, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. J. M. Lee, S. R. Kim, S. J. Yoo, O. K. Hong, H. S. Son, and S. A. Chang, “The relationship between adipokines, metabolic parameters and insulin resistance in patients with metabolic syndrome and type 2 diabetes,” Journal of International Medical Research, vol. 37, no. 6, pp. 1803–1812, 2009. View at Google Scholar · View at Scopus
  15. Y. Okamoto, S. Kihara, T. Funahashi, Y. Matsuzawa, and P. Libby, “Adiponectin: a key adipocytokine in metabolic syndrome,” Clinical Science, vol. 110, no. 3, pp. 267–278, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Kressel, B. Trunz, A. Bub et al., “Systemic and vascular markers of inflammation in relation to metabolic syndrome and insulin resistance in adults with elevated atherosclerosis risk,” Atherosclerosis, vol. 202, no. 1, pp. 263–271, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Jin, F. Yang, I. Yang et al., “Uric acid, hyperuricemia and vascular diseases,” Frontiers in Bioscience, vol. 17, no. 2, pp. 656–669, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Panarotto, J. L. Ardilouze, D. Tessier, and P. Maheux, “The degree of hyperinsulinemia and impaired glucose tolerance predicts plasma leptin concentrations in women only: a new exploratory paradigm,” Metabolism, vol. 49, no. 8, pp. 1055–1062, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Lichnovská, S. Gwozdziewiczová, R. Chlup, and J. Hrebícek, “Serum leptin in the development of insulin resistance and other disorders in the metabolic syndrome,” Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic, vol. 149, no. 1, pp. 119–126, 2005. View at Google Scholar · View at Scopus
  20. World Health organization (WHO), “BMI classification,” April 2012, http://apps.who.int/bmi/index.jsp?introPage=intro_3.html.
  21. D. R. Matthews, J. P. Hosker, and A. S. Rudenski, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985. View at Google Scholar · View at Scopus
  22. A. Esteghamati, H. Ashraf, O. Khalilzadeh et al., “Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007),” Nutrition and Metabolism, vol. 7, article 26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. W. C. Li, K. Y. Hsiao, I. C. Chen, Y. C. Chang, S. H. Wang, and K. H. Wu, “Serum leptin is associated with cardiometabolic risk and predicts metabolic syndrome in Taiwanese adults,” Cardiovascular Diabetology, vol. 10, article 36, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. S. M. Grundy, H. B. Brewer, J. I. Cleeman, S. C. Smith, and C. Lenfant, “Definition of metabolic syndrome-report of the national heart lung and blood institute/ American heart association conference on scientific issues related to definition,” Circulation, vol. 109, no. 3, pp. 433–438, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. P. M. Ridker, J. E. Buring, N. R. Cook, and N. Rifai, “C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women,” Circulation, vol. 107, no. 3, pp. 391–397, 2003. View at Google Scholar · View at Scopus
  26. H. Sumino, S. Ichikawa, T. Kanda, T. Nakamura, and T. Sakamaki, “Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia,” The Lancet, vol. 354, no. 9179, p. 650, 1999. View at Google Scholar · View at Scopus
  27. J. Licinio-Paixao, K. S. Polonsky, and B. D. Given, “Ingestion of a mixed meal does not affect the metabolic clearance rate of biosynthetic human C-peptide,” Journal of Clinical Endocrinology and Metabolism, vol. 63, no. 2, pp. 401–403, 1986. View at Google Scholar · View at Scopus
  28. B. Gumbiner, K. S. Polonsky, W. F. Beltz et al., “Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus,” Journal of Clinical Endocrinology and Metabolism, vol. 70, no. 6, pp. 1594–1602, 1990. View at Google Scholar · View at Scopus
  29. O. K. Faber, C. Hagen, and C. Binder, “Kinetics of human connecting peptide in normal and diabetic subjects,” Journal of Clinical Investigation, vol. 62, no. 1, pp. 197–203, 1978. View at Google Scholar · View at Scopus
  30. V. Razvan, S. Ifrim, and C. Ionescu-Tirgoviste, “Association of proinsulin with cardiovascular risk in nondiabetic subjects,” Proceedings of the Romanian Academy B, vol. 2, pp. 129–136, 2011. View at Google Scholar